Cardiology Department, CHU Saint-Pierre, Université Libre de Bruxelles, 322 rue Haute, B-1000, Brussels, Belgium.
Quebec Heart &Lung Institute, Department of Medicine, Laval University, Chemin Sainte-Foy, Quebec City, QC, G1V 4G5, Canada.
Nat Rev Cardiol. 2016 Jul;13(7):429-40. doi: 10.1038/nrcardio.2016.57. Epub 2016 Apr 28.
Multivalvular disease (MVD) is common among patients with valvular disease, and has a complex pathophysiology dependent on the specific combination of valve lesions. Diagnosis is challenging because several echocardiographic methods commonly used for the assessment of stenosis or regurgitation have been validated only in patients with single-valve disease. Decisions about the timing and type of treatment should be made by a multidisciplinary heart valve team, on a case-by-case basis. Several factors should be considered, including the severity and consequences of the MVD, the patient's life expectancy and comorbidities, the surgical risk associated with combined valve procedures, the long-term risk of morbidity and mortality associated with multiple valve prostheses, and the likelihood and risk of reoperation. The introduction of transcatheter valve therapies into clinical practice has provided new treatment options for patients with MVD, and decision-making algorithms on how to combine surgical and percutaneous treatment options are evolving rapidly. In this Review, we discuss the pathophysiology, diagnosis, and treatment of MVD, focusing on the combinations of valve pathologies that are most often encountered in clinical practice.
多瓣膜病(MVD)在瓣膜病患者中较为常见,其病理生理学较为复杂,取决于特定的瓣膜病变组合。由于几种常用于评估狭窄或反流的超声心动图方法仅在单瓣膜病患者中得到验证,因此诊断具有挑战性。关于治疗时机和类型的决策应由多学科心脏瓣膜团队根据具体情况做出。应考虑多种因素,包括 MVD 的严重程度和后果、患者的预期寿命和合并症、联合瓣膜手术相关的手术风险、多个瓣膜假体相关的长期发病率和死亡率风险,以及再次手术的可能性和风险。经导管瓣膜治疗在临床实践中的应用为 MVD 患者提供了新的治疗选择,如何结合手术和经皮治疗选择的决策算法正在迅速发展。在这篇综述中,我们讨论了 MVD 的病理生理学、诊断和治疗,重点介绍了在临床实践中最常遇到的瓣膜病变组合。